Skip to main content
Fig. 11 | BMC Cancer

Fig. 11

From: Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion

Fig. 11

SKI-II alone and in combination with temozolomide (TMZ) impairs invasion of MGMT-positive glioblastoma cells. A, B The spheroid invasion assay was performed with U3054 cells (mesenchymal GB) treated with vehicle control (DMSO), 48 µM TMZ, 2.66 µM SKI-II, and the combination (TMZ + SKI-II) for up to 5 days under normoxia (21% O2) and hypoxia (3% O2). Quantification of the invaded area was performed using the Spheroid Analyzer (CLADIAC) as described in Material and Methods. (Ai) Light microscopy images of treated U3054 spheroids and respective surface plots. Data represent mean (± SD) of n = 3. Two-way ANOVA followed by Tukey’s multiple comparisons test was performed for statistical analysis. Scale bar = 500 µm

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us